A Real Life Evaluation of the Performance of a Large Volume Nebulizer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Arkansas Children's Hospital Research Institute.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
S&T Medical Technologies Inc
Information provided by:
Arkansas Children's Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT00632112
First received: February 29, 2008
Last updated: June 3, 2009
Last verified: June 2009

February 29, 2008
June 3, 2009
March 2008
July 2009   (final data collection date for primary outcome measure)
Nebulizer solution output [ Time Frame: every 2 hours for first 6 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00632112 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Real Life Evaluation of the Performance of a Large Volume Nebulizer
A Real Life Evaluation of the Performance of a Large Volume Nebulizer

Continuous albuterol has become the standard of care for patients in status asthmaticus. We have previously performed an in-vitro study comparing 4 different brands of continuous nebulizers. We now want to compare the in-vitro with the in-vivo performance of the brand we use. we hypothesize that there will be no difference between in-vivo and in-vitro results.

There will be no intervention to the patients. Nebulizers will be used as per current policies and procedures. They will only be marked on the outside at the water level every 2 hours for the first 6 hours. Once ready to be discarded will be collected for laboratory testing Once in the laboratory, nebulizers will be weight on a precision scale without liquid, then they will be filled with normal saline to the first mark (6th hour) and re-weight. The nebulizers will be filled to next mark and re-weight until 200 mls. of total volume are achieved. Solution output will be calculated as the weight difference between the 2 hour periods.

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Pediatric patients admitted to the Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.

Asthma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
Not Provided
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pediatric patients admitted to Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.

Exclusion Criteria:

  • Patients requiring invasive or non-invasive ventilation.
Both
up to 21 Years
No
Contact: Ariel Berlinski, M.D. 501-364-1006 berlinskiariel@uams.edu
United States
 
NCT00632112
98551
No
Ariel Berlinski, University of Arkansas for Medical Sciences
Arkansas Children's Hospital Research Institute
S&T Medical Technologies Inc
Principal Investigator: Ariel Berlinski, M.D. University of Arkansas
Arkansas Children's Hospital Research Institute
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP